• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病的临床与综合管理

The clinical and integrated management of COPD.

作者信息

Bettoncelli G, Blasi F, Brusasco V, Centanni S, Corrado A, De Benedetto F, De Michele F, Di Maria G U, Donner C F, Falcone F, Mereu C, Nardini S, Pasqua F, Polverino M, Rossi A, Sanguinetti C M

机构信息

.

出版信息

Sarcoidosis Vasc Diffuse Lung Dis. 2014 May 12;31 Suppl 1:3-21.

PMID:24820963
Abstract

COPD is a chronic pathological condition of the respiratory system characterized by persistent and partially reversible airflow obstruction, to which variably contribute remodeling of bronchi (chronic bronchitis), bronchioles (small airway disease) and lung parenchyma (pulmonary emphysema). COPD can cause important systemic effects and be associated with complications and comorbidities. The diagnosis of COPD is based on the presence of respiratory symptoms and/or a history of exposure to risk factors, and the demonstration of airflow obstruction by spirometry. GARD of WHO has defined COPD "a preventable and treatable disease". The integration among general practitioner, chest physician as well as other specialists, whenever required, assures the best management of the COPD person, when specific targets to be achieved are well defined in a diagnostic and therapeutic route, previously designed and shared with appropriateness. The first-line pharmacologic treatment of COPD is represented by inhaled long-acting bronchodilators. In symptomatic patients, with pre-bronchodilator FEV1 < 60%predicted and ≥ 2 exacerbations/year, ICS may be added to LABA. The use of fixed-dose, single-inhaler combination may improve the adherence to treatment. Long term oxygen therapy (LTOT) is indicated in stable patients, at rest while receiving the best possible treatment, and exhibiting a PaO2 ≤ 55 mmHg (SO2<88%) or PaO2 values between 56 and 59 mmHg (SO2 < 89%) associated with pulmonary arterial hypertension, cor pulmonale, or edema of the lower limbs or hematocrit > 55%. Respiratory rehabilitation is addressed to patients with chronic respiratory disease in all stages of severity who report symptoms and limitation of their daily activity. It must be integrated in an individual patient tailored treatment as it improves dyspnea, exercise performance, and quality of life. Acute exacerbation of COPD is a sudden worsening of usual symptoms in a person with COPD, over and beyond normal daily variability that requires treatment modification. The pharmacologic therapy can be applied at home and includes the administration of drugs used during the stable phase by increasing the dose or modifying the route, and adding, whenever required, drugs as antibiotics or systemic corticosteroids. In case of patients who because of COPD severity and/or of exacerbations do not respond promptly to treatment at home hospital admission should be considered. Patients with "severe or "very severe COPD who experience exacerbations should be carried out in respiratory unit, based on the severity of acute respiratory failure. An integrated system is required in the community in order to ensure adequate treatments also outside acute care hospital settings and rehabilitation centers. This article is being simultaneusly published in Multidisciplinary Respiratory Medicine 2014; 9:25.

摘要

慢性阻塞性肺疾病(COPD)是一种呼吸系统的慢性病理状态,其特征为持续性且部分可逆的气流受限,支气管(慢性支气管炎)、细支气管(小气道疾病)和肺实质(肺气肿)的重塑在其中起到不同程度的作用。COPD可导致重要的全身影响,并伴有并发症和合并症。COPD的诊断基于呼吸道症状的存在和/或危险因素暴露史,以及通过肺量计证实存在气流受限。世界卫生组织全球慢性阻塞性肺疾病防治创议(GARD)将COPD定义为“一种可预防和可治疗的疾病”。全科医生、胸科医生以及其他专科医生之间的协作,在必要时可确保对COPD患者进行最佳管理,前提是在预先设计并合理共享的诊断和治疗路径中明确了要实现的具体目标。COPD的一线药物治疗以吸入长效支气管扩张剂为代表。对于有症状且支气管扩张剂使用前第一秒用力呼气容积(FEV1)<60%预计值且每年≥2次加重的患者,可在长效β2受体激动剂(LABA)基础上加用吸入性糖皮质激素(ICS)。使用固定剂量的单一吸入器组合可能会提高治疗依从性。长期氧疗(LTOT)适用于病情稳定的患者,这些患者在接受最佳治疗的同时处于静息状态,且动脉血氧分压(PaO2)≤55 mmHg(血氧饱和度<88%)或PaO2在56至59 mmHg之间(血氧饱和度<89%),伴有肺动脉高压、肺心病、下肢水肿或血细胞比容>55%。呼吸康复适用于所有严重程度阶段、有症状且日常活动受限的慢性呼吸道疾病患者。它必须纳入针对个体患者的定制治疗中,因为它可改善呼吸困难、运动能力和生活质量。COPD急性加重是指COPD患者的日常症状突然恶化,超出正常的每日变化范围,需要调整治疗。药物治疗可在家中进行,包括增加稳定期使用药物的剂量或改变给药途径,并在必要时加用抗生素或全身用糖皮质激素等药物。对于因COPD严重程度和/或急性加重而在家中对治疗反应不迅速的患者,应考虑住院治疗。对于经历急性加重的“重度”或“极重度”COPD患者,应根据急性呼吸衰竭的严重程度在呼吸科病房进行治疗。社区需要一个综合系统,以确保在急性护理医院环境和康复中心之外也能提供充分的治疗。本文同时发表于《多学科呼吸医学》2014年;9:25。

相似文献

1
The clinical and integrated management of COPD.慢性阻塞性肺疾病的临床与综合管理
Sarcoidosis Vasc Diffuse Lung Dis. 2014 May 12;31 Suppl 1:3-21.
2
The clinical and integrated management of COPD. An official document of AIMAR (Interdisciplinary Association for Research in Lung Disease), AIPO (Italian Association of Hospital Pulmonologists), SIMER (Italian Society of Respiratory Medicine), SIMG (Italian Society of General Medicine).慢性阻塞性肺疾病的临床与综合管理。AIMAR(肺部疾病跨学科研究协会)、AIPO(意大利医院肺科医生协会)、SIMER(意大利呼吸医学协会)、SIMG(意大利普通医学协会)的官方文件。
Multidiscip Respir Med. 2014 May 19;9(1):25. doi: 10.1186/2049-6958-9-25. eCollection 2014.
3
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.慢性阻塞性肺疾病稳定期的诊断与管理:美国医师学会、美国胸科学会、美国胸科学会和欧洲呼吸学会的临床实践指南更新。
Ann Intern Med. 2011 Aug 2;155(3):179-91. doi: 10.7326/0003-4819-155-3-201108020-00008.
4
Common lung conditions: chronic obstructive pulmonary disease.常见肺部疾病:慢性阻塞性肺疾病
FP Essent. 2013 Jun;409:23-31.
5
COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update.COPD-X 澳大利亚和新西兰慢性阻塞性肺疾病诊断和管理指南:2017 年更新版。
Med J Aust. 2017 Nov 20;207(10):436-442. doi: 10.5694/mja17.00686.
6
Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society.慢性阻塞性肺疾病 - 稳定期疾病的诊断和管理;基于临床表型的可治疗特征概念,采用个体化护理方法。捷克肺病和结核学会立场文件。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Dec;164(4):325-356. doi: 10.5507/bp.2020.056.
7
COPD management. Part I. Strategies for managing the burden of established COPD.慢性阻塞性肺疾病的管理。第一部分。应对已确诊慢性阻塞性肺疾病负担的策略。
Int J Tuberc Lung Dis. 2008 Jun;12(6):586-94.
8
[Acute exacerbations of chronic obstructive pulmonary disease].[慢性阻塞性肺疾病急性加重]
Presse Med. 2009 Mar;38(3):485-95. doi: 10.1016/j.lpm.2008.12.014. Epub 2009 Jan 29.
9
Innovations to achieve excellence in COPD diagnosis and treatment in primary care.在初级保健中实现 COPD 诊断和治疗卓越的创新。
Postgrad Med. 2010 Sep;122(5):150-64. doi: 10.3810/pgm.2010.09.2212.
10
Guideline for the management of chronic obstructive pulmonary disease--2011 update.慢性阻塞性肺疾病管理指南——2011 年更新版。
S Afr Med J. 2011 Jan;101(1 Pt 2):63-73.

引用本文的文献

1
lncRNA GAS5 promotes pyroptosis in COPD by functioning as a ceRNA to regulate the miR‑223‑3p/NLRP3 axis.长链非编码 RNA GAS5 通过作为 ceRNA 调节 miR-223-3p/NLRP3 轴促进 COPD 中的细胞焦亡。
Mol Med Rep. 2022 Jul;26(1). doi: 10.3892/mmr.2022.12735. Epub 2022 May 18.
2
[Not Available].[无可用内容]。
Drug Target Insights. 2021 Nov 13;15:21-25. doi: 10.33393/dti.2021.2291. eCollection 2021 Jan-Dec.
3
Spirometry evaluation to assess performance of a claims-based predictive model identifying patients with undiagnosed COPD.
通过肺量计评估来评估一种基于索赔数据的预测模型识别未确诊慢性阻塞性肺疾病(COPD)患者的性能。
Int J Chron Obstruct Pulmon Dis. 2019 Feb 15;14:439-446. doi: 10.2147/COPD.S187947. eCollection 2019.
4
Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis.长效支气管扩张剂改善 COPD 患者的运动能力:系统评价和荟萃分析。
Respir Res. 2018 Jan 24;19(1):18. doi: 10.1186/s12931-018-0721-3.
5
Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies.伴有轻度气流受限的慢性阻塞性肺疾病:当前认知与未来研究建议——六家科学学会的共识文件
Int J Chron Obstruct Pulmon Dis. 2017 Aug 29;12:2593-2610. doi: 10.2147/COPD.S132236. eCollection 2017.
6
Sphingosine 1-Phosphate: A Novel Target for Lung Disorders.鞘氨醇-1-磷酸:肺部疾病的新靶点。
Front Immunol. 2017 Mar 14;8:296. doi: 10.3389/fimmu.2017.00296. eCollection 2017.
7
Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids?优化老年慢性阻塞性肺疾病患者的治疗:吸入性糖皮质激素起什么作用?
Drugs Aging. 2015 Sep;32(9):679-87. doi: 10.1007/s40266-015-0291-8.
8
Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.茚达特罗-格隆溴铵联合双重支气管扩张在慢性阻塞性肺疾病管理中的临床作用:对患者相关结局和生活质量的影响。
Int J Chron Obstruct Pulmon Dis. 2015 Jul 23;10:1383-92. doi: 10.2147/COPD.S55488. eCollection 2015.